Sargramostim for Myeloid Dendritic Cell Deficiency

Johns Hopkins University

Status and phase

Completed

Phase 1

Conditions

Dendritic Cell Deficiency

Treatments

Drug: Sargramostim

Study type

Interventional

Funder types

Other

Identifiers

NCT01871467

KW-5001-1

Details and patient eligibility

About

Previous studies have demonstrated a deficiency of blood dendritic cells in patients with kidney disease that is associated with the development of viral infections after kidney transplantation. We plan to test the ability of sargramostim to increase blood dendritic cell levels in patients with kidney disease in the hopes of developing new therapies to prevent viral infections after kidney transplantation.

Enrollment

2 patients

Sex

All

Ages

18 to 80 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Age >18 years < 80 years with diagnosis of end stage renal disease and currently undergoing outpatient hemodialysis (HD) at one of the Johns Hopkins University-affiliated HD units

Exclusion criteria

Age<18or>80years
History of non-adherence to prescribed HD treatment
Active drug or heavy alcohol use (defined as > 4 drinks/day)
Pregnancy or breast feeding
Active infection (bacterial or viral) or clinically significant infections within the past three months (e.g. those requiring hospitalization, or as judged by the PI)
Active malignancy (with the exception of excised non-metastatic basal cell carcinoma or squamous cell carcinoma of the skin, or adequately treated pre- invasive cervical cancer in situ)
Unstable cardiovascular status (angina, arrhythmias, congestive heart failure etc...)
History of liver disease (as defined by a diagnosis of uncompensated cirrhosis) • History of lung disease (including moderate-severe chronic obstructive pulmonary disease, interstitial lung disease, or asthma)
Known hypersensitivity to yeast-derived products
Hemoglobin < 10 g/dL and hematocrit < 30%.
Abnormal white blood cell (WBC) count at baseline (< 3 or > 12 x 10 cells/mm )
Treatment with WBC growth factors (G-CSF or GM-CSF) or immunosuppressive medications (tacrolimus, cyclosporine, mycophenolate, azathioprine, corticosteroids, chlorambucil, cyclophosphamide) within 4 weeks of study (erythropoiesis-stimulating agents will be allowed)
Treatment with lithium within 4 weeks of study